Quarterly report pursuant to Section 13 or 15(d)


1 Months Ended 9 Months Ended
Jan. 11, 2022
May 27, 2022
Mar. 30, 2022
Sep. 30, 2023
Dec. 31, 2022
Sep. 30, 2019
Dec. 10, 2015
Renumeration amount       $ 3,000      
Consideration amount $ 657,640     503,089      
First payment owed $ 145,000            
Attorney's fees   $ 222,933 $ 222,933 $ 235,886      
Interest rate       10.00%      
Accrual of loss on contingency       $ (322,000)      
Compensation for services, description       As of May 14, 2021, the Company has entered into four consulting agreements. In compensation for services: (i) one consultant shall receive a renumeration amount of $10,000-$12,500 per month and has earned 1% of the Company’s majority owned subsidiary, BioCorRx Pharmaceuticals as of May 7, 2021 based on FDA clearance of Company’s IND application; consulting agreement terminated in April 2021 (ii) one consultant shall receive common stock equivalent to $1,375 on the last day of each month; (iii) two consultants shall receive common stock equivalent to $3,750 on the last day of each month; and (iv) one consultant shall receive a remuneration amount of $3,500 per month      
Charles River Laboratories, Inc. [Member]              
Total amended consideration       $ 3,024,476      
Remaining commitment       $ 28,936      
BICX Holding Company LLC [Member]              
Common stock issued upon convertible debt       2,227,575      
Convertible Promissory Note           $ 4,160,000  
Conversion agreement description       Pursuant to the Conversion Agreement, BICX has agreed that the Total Interest Payment (as defined in the Conversion Agreement) that would have been due under the Note, in the amount of $1,138,157, will be reflected on the Company’s financial statements as an amount due and owing to the Investor to be repaid within twelve (12) months of the closing of the Public Offering, or if the Public Offering is terminated or abandoned prior to closing, then on or before such date that is no later than twelve (12) months from the date of such termination or abandonment      
Issuance price       $ 2.00      
Amount due to investor       $ 1,138,157      
Board Member [Member]              
Receive common stock equivalent       5,000      
Alpine Creek [Member]              
Royalty due       91 $ 91    
Total consideration amount       1,531,926      
Payables to Alpine Creek             $ 1,215,000
Paid to Alpine Creek       $ 1,620,000      
Payable per treatment sold             $ 100
Other payment description       Company shall pay 2.5% of the Company’s gross profit for implant distribution not to exceed $100 per sale      
Profit holding percentage             50.00%